Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Share:
Related ILMN
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector
Benzinga's Top Upgrades, Downgrades For January 18, 2017
Rockefeller Financial Services Inc Buys Facebook Inc, Synchrony Financial, Cemex SAB de CV, ... (GuruFocus)

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

DateFirmActionFromTo
Jan 2017Deutsche BankInitiates Coverage OnHold
Jan 2017Bank of AmericaUpgradesNeutralBuy
Nov 2016Leerink SwannAssumesMarket Perform

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!